People · Operator

Alex Khowaylo

Named in public records as an officer, director or promoter · active 2011–2022 · Software / Tech, Biotechnology

3
Companies
5
Filings
$33.7M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Acuitive Technologies, Inc.Software / TechSeries A$22.5M$90.3M2021
Pipeline Biomedical, Inc.BiotechnologySeries A$8.0M$289.2M2011
Pipeline Biomedical Holdings, Inc.BiotechnologySeed$3.2M$142.1M2012
Operator network

Alex Khowaylo at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Alex S. Khowaylo · 1 companies · 1 sharedAlex S. KhowayloGary S. Fischetti · 1 companies · 1 sharedGary S. FischettiJames S. Maylayter · 1 companies · 1 sharedJames S. MaylayterMichael S. McCarthy · 1 companies · 1 sharedMichael S. McCart…Vincent S. Forlenza · 1 companies · 1 sharedVincent S. Forlen…David S. Washburn · 3 companies · 3 sharedDavid S. WashburnMichael P. McCarthy · 3 companies · 3 sharedMichael P. McCart…Larry P. Feinberg · 2 companies · 2 sharedLarry P. FeinbergRobert C. Cohen · 2 companies · 2 sharedRobert C. CohenAcuitive Technologies, Inc. · $22.5M raisedAcuitive Technologies…Pipeline Biomedical, Inc. · $8.0M raisedPipeline Biomedical, …Pipeline Biomedical Holdings, Inc. · $3.2M raisedPipeline Biomedical H…Alex KhowayloAK
Alex Khowaylo Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Alex Khowaylo on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
David S. Washburn33
Michael P. McCarthy33
Larry P. Feinberg22
Robert C. Cohen22
Michael S. McCarthy11
Vincent S. Forlenza11
Gary S. Fischetti11
James S. Maylayter11
Alex S. Khowaylo11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.